{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:45:15Z","timestamp":1792813515621,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.vaccine.2021.06.049","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:26:24Z","timestamp":1625531184000},"page":"7277-7285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["MTBVAC, a live TB vaccine poised to initiate efficacy trials 100\u00a0years after BCG"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-5478","authenticated-orcid":false,"given":"Carlos","family":"Mart\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dessislava","family":"Marinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nacho","family":"Aguil\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8841-6593","authenticated-orcid":false,"given":"Jes\u00fas","family":"Gonzalo-Asensio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.06.049_b0005","unstructured":"WHO. World Health Organization Global Tuberculosis Report 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.2020."},{"key":"10.1016\/j.vaccine.2021.06.049_b0010","unstructured":"https:\/\/www.who.int\/teams\/health-product-and-policy-standards\/standards-and-specifications\/vaccines-quality\/bcg. BCG Vaccine."},{"key":"10.1016\/j.vaccine.2021.06.049_b0015","unstructured":"WHO. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665\/325771. 2019."},{"key":"10.1016\/j.vaccine.2021.06.049_b0020","unstructured":"WHO. BCG vaccines: WHO position paper. Weekly Epidemiological Record. 8 (93): 73\u201396. 23 February 2018 Geneva, Switzerland2018."},{"key":"10.1016\/j.vaccine.2021.06.049_b0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1542\/peds.96.1.29","article-title":"The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature","volume":"96","author":"Colditz","year":"1995","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.06.049_b0030","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1001\/jama.291.17.2086","article-title":"Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study","volume":"291","author":"Aronson","year":"2004","journal-title":"JAMA"},{"issue":"1\u2013372","key":"10.1016\/j.vaccine.2021.06.049_b0035","first-page":"v","article-title":"Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis","volume":"17","author":"Abubakar","year":"2013","journal-title":"Health Technology Assessment"},{"key":"10.1016\/j.vaccine.2021.06.049_b0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1473-3099(15)00400-4","article-title":"Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study","volume":"16","author":"Nguipdop-Djomo","year":"2016","journal-title":"Lancet Infectious Diseases"},{"key":"10.1016\/j.vaccine.2021.06.049_b0045","unstructured":"WHO. WHO Coronavirus Disease (COVID-19) Dashboard. https:\/\/covid19.who.int\/."},{"key":"10.1016\/j.vaccine.2021.06.049_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100603","article-title":"The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis","volume":"28","author":"Cilloni","year":"2020","journal-title":"EClinicalMedicine."},{"key":"10.1016\/j.vaccine.2021.06.049_b0055","unstructured":"WHO. WHO End TB Strategy. WHO\/CDS\/TB\/2018.29 \u2013 \u00a9 World Health Organization 2018. , https:\/\/www.who.int\/tb\/End_TB_brochure.pdf?ua=1."},{"key":"10.1016\/j.vaccine.2021.06.049_b0060","article-title":"WHO Preferred Product Characteristics for New Tuberculosis Vaccines","author":"WHO","year":"2018","journal-title":"Ordering code: WHO\/IVB\/18.06"},{"key":"10.1016\/j.vaccine.2021.06.049_b0065","unstructured":"www.tbvi.eu. TuBerculosis Vaccine Initiative (TBVI)."},{"key":"10.1016\/j.vaccine.2021.06.049_b0070","doi-asserted-by":"crossref","unstructured":"Martin C, Aguilo, N., Marinova, D., & Gonzalo-Asensio, J. Update on TB vaccine pipeline. Applied Sciences (Switzerland), 10(7) http:\/\/doiorg\/103390\/app10072632. 2020.","DOI":"10.3390\/app10072632"},{"key":"10.1016\/j.vaccine.2021.06.049_b0075","unstructured":"Douglas Young P. Research and develoment of new TB vaccines. International TB Vaccine Symposium Paraninfo Building, University of Zaragoza, Zaragoza, Spain. Sponsors\/Organizers: Fundaci\u00f3n Ram\u00f3n Areces, TBVI, University of Zaragoza3-4 June 2010."},{"key":"10.1016\/j.vaccine.2021.06.049_b0080","doi-asserted-by":"crossref","first-page":"10955","DOI":"10.1073\/pnas.94.20.10955","article-title":"Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis","volume":"94","author":"Pelicic","year":"1997","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2021.06.049_b0085","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1128\/jb.176.2.535-539.1994","article-title":"Efficient transposition in mycobacteria: construction of Mycobacterium smegmatis insertional mutant libraries","volume":"176","author":"Guilhot","year":"1994","journal-title":"Journal of Bacteriology"},{"key":"10.1016\/j.vaccine.2021.06.049_b0090","first-page":"171","article-title":"Towards new mycobacterial vaccines","volume":"82","author":"Gicquel","year":"1994","journal-title":"Developments in Biological Standardization"},{"key":"10.1016\/j.vaccine.2021.06.049_b0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2958.1992.tb00842.x","article-title":"Isolation and analysis of IS6120, a new insertion sequence from Mycobacterium smegmatis","volume":"6","author":"Guilhot","year":"1992","journal-title":"Molecular Microbiology"},{"key":"10.1016\/j.vaccine.2021.06.049_b0100","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/345739a0","article-title":"Transposition of an antibiotic resistance element in mycobacteria","volume":"345","author":"Martin","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.06.049_b0105","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1128\/jb.172.5.2793-2797.1990","article-title":"Functional analysis of pAL5000, a plasmid from Mycobacterium fortuitum: construction of a \u201cmini\u201d mycobacterium-Escherichia coli shuttle vector","volume":"172","author":"Ranes","year":"1990","journal-title":"Journal of Bacteriology"},{"key":"10.1016\/j.vaccine.2021.06.049_b0110","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1016\/j.vaccine.2005.03.001","article-title":"New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development","volume":"23","author":"Kamath","year":"2005","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.06.049_b0115","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1016\/j.vaccine.2013.07.051","article-title":"Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials","volume":"31","author":"Arbues","year":"2013","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.06.049_b0120","doi-asserted-by":"crossref","first-page":"16085","DOI":"10.1038\/ncomms16085","article-title":"Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis","volume":"8","author":"Aguilo","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.vaccine.2021.06.049_b0125","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/infdis\/jix030","article-title":"Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis","volume":"216","author":"Clark","year":"2017","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.vaccine.2021.06.049_b0130","article-title":"MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies","author":"White","year":"202164","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2021.06.049_b0135","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/14760584.2017.1324303","article-title":"MTBVAC from discovery to clinical trials in tuberculosis-endemic countries","volume":"16","author":"Marinova","year":"2017","journal-title":"Expert Rev Vaccines."},{"key":"10.1016\/j.vaccine.2021.06.049_b0140","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1073\/pnas.052548299","article-title":"A new evolutionary scenario for the Mycobacterium tuberculosis complex","volume":"99","author":"Brosch","year":"2002","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2021.06.049_b0145","series-title":"Brosch R","first-page":"4","author":"Boritsch","year":"2016"},{"key":"10.1016\/j.vaccine.2021.06.049_b0150","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1073\/pnas.0700869104","article-title":"Genome plasticity of BCG and impact on vaccine efficacy","volume":"104","author":"Brosch","year":"2007","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2021.06.049_b0155","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/ng.590","article-title":"Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved","volume":"42","author":"Comas","year":"2010","journal-title":"Nature Genetics"},{"key":"10.1016\/j.vaccine.2021.06.049_b0160","first-page":"3751","article-title":"Mycobacterium tuberculosis Complex Exhibits Lineage-Specific Variations Affecting Protein Ductility and Epitope Recognition","volume":"8","author":"Yruela","year":"2016","journal-title":"Genome Biol Evol."},{"key":"10.1016\/j.vaccine.2021.06.049_b0165","article-title":"Genome sequencing and analysis of BCG vaccine strains","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.06.049_b0170","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1016\/j.vaccine.2014.07.113","article-title":"Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG)","volume":"32","author":"Copin","year":"2014","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.06.049_b0175","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3389\/fimmu.2017.01803","article-title":"MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic","volume":"8","author":"Gonzalo-Asensio","year":"2017","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.vaccine.2021.06.049_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006111","article-title":"Within Host Evolution Selects for a Dominant Genotype of Mycobacterium tuberculosis while T Cells Increase Pathogen Genetic Diversity","volume":"12","author":"Copin","year":"2016","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.vaccine.2021.06.049_b0185","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/mt.2015.216","article-title":"Variable Virulence and Efficacy of BCG Vaccine Strains in Mice and Correlation With Genome Polymorphisms","volume":"24","author":"Zhang","year":"2016","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.vaccine.2021.06.049_b0190","doi-asserted-by":"crossref","first-page":"11491","DOI":"10.1073\/pnas.1406693111","article-title":"Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator","volume":"111","author":"Gonzalo-Asensio","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2021.06.049_b0195","doi-asserted-by":"crossref","first-page":"20433","DOI":"10.1038\/s41598-020-77249-x","article-title":"The value of the continuous genotyping of multi-drug resistant tuberculosis over 20 years in Spain","volume":"10","author":"Iglesias","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.vaccine.2021.06.049_b0200","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/317547","article-title":"High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain B","volume":"32","author":"Rivero","year":"2001","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.vaccine.2021.06.049_b0205","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tube.2016.06.005","article-title":"In-depth analysis of the genome sequence of a clinical, extensively drug-resistant Mycobacterium bovis strain","volume":"100","author":"Sagasti","year":"2016","journal-title":"Tuberculosis (Edinb)."},{"key":"10.1016\/j.vaccine.2021.06.049_b0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007282","article-title":"New insights into the transposition mechanisms of IS6110 and its dynamic distribution between Mycobacterium tuberculosis Complex lineages","volume":"14","author":"Gonzalo-Asensio","year":"2018","journal-title":"PLoS Genetics"},{"key":"10.1016\/j.vaccine.2021.06.049_b0215","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2958.2001.02500.x","article-title":"An essential role for phoP in Mycobacterium tuberculosis virulence","volume":"41","author":"Perez","year":"2001","journal-title":"Molecular Microbiology"},{"key":"10.1016\/j.vaccine.2021.06.049_b0220","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/ng.3704","article-title":"Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages","volume":"48","author":"Stucki","year":"2016","journal-title":"Nature Genetics"},{"key":"10.1016\/j.vaccine.2021.06.049_b0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003496","article-title":"PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence","volume":"3","author":"Gonzalo-Asensio","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.06.049_b0230","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1128\/IAI.01824-14","article-title":"A specific polymorphism in Mycobacterium tuberculosis H37Rv causes differential ESAT-6 expression and identifies WhiB6 as a novel ESX-1 component","volume":"82","author":"Solans","year":"2014","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.vaccine.2021.06.049_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004183","article-title":"The PhoP-dependent ncRNA Mcr7 modulates the TAT secretion system in Mycobacterium tuberculosis","volume":"10","author":"Solans","year":"2014","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.vaccine.2021.06.049_b0240","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1128\/JB.01465-07","article-title":"A point mutation in the two-component regulator PhoP-PhoR accounts for the absence of polyketide-derived acyltrehaloses but not that of phthiocerol dimycocerosates in Mycobacterium tuberculosis H37Ra","volume":"190","author":"Chesne-Seck","year":"2008","journal-title":"Journal of Bacteriology"},{"key":"10.1016\/j.vaccine.2021.06.049_b0245","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1074\/jbc.C500388200","article-title":"The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis","volume":"281","author":"Gonzalo Asensio","year":"2006","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.vaccine.2021.06.049_b0250","article-title":"Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP","author":"Frigui","year":"2008433","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.vaccine.2021.06.049_b0255","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.vaccine.2009.12.083","article-title":"The second Geneva Consensus: Recommendations for novel live TB vaccines","volume":"28","author":"Walker","year":"2010","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.06.049_b0260","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/47042","article-title":"Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice","volume":"402","author":"Cox","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.06.049_b0265","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.molcel.2005.02.009","article-title":"Dissecting the mechanism and assembly of a complex virulence mycobacterial lipid","volume":"17","author":"Trivedi","year":"2005","journal-title":"Molecular Cell"},{"key":"10.1016\/j.vaccine.2021.06.049_b0270","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1128\/IAI.00097-11","article-title":"Spontaneous phthiocerol dimycocerosate-deficient variants of Mycobacterium tuberculosis are susceptible to gamma interferon-mediated immunity","volume":"79","author":"Kirksey","year":"2011","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.vaccine.2021.06.049_b0275","doi-asserted-by":"crossref","first-page":"19845","DOI":"10.1074\/jbc.M100662200","article-title":"Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall permeability barrier","volume":"276","author":"Camacho","year":"2001","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.vaccine.2021.06.049_b0280","doi-asserted-by":"crossref","DOI":"10.1111\/cmi.12726","article-title":"ESX-1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosis","volume":"19","author":"Augenstreich","year":"2017","journal-title":"Cellular Microbiology"},{"key":"10.1016\/j.vaccine.2021.06.049_b0285","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2249.2005.02832.x","article-title":"Immunogenicity and protective efficacy of the Mycobacterium tuberculosis fadD26 mutant","volume":"141","author":"Infante","year":"2005","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1016\/j.vaccine.2021.06.049_b0290","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tube.2015.10.010","article-title":"MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice","volume":"96","author":"Aguilo","year":"2016","journal-title":"Tuberculosis (Edinb)."},{"key":"10.1016\/j.vaccine.2021.06.049_b0295","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1016\/j.vaccine.2006.03.017","article-title":"The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs","volume":"24","author":"Martin","year":"2006","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.06.049_b0300","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S2213-2600(15)00435-X","article-title":"Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial","volume":"3","author":"Spertini","year":"2015","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.vaccine.2021.06.049_b0305","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S2213-2600(19)30251-6","article-title":"Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial","volume":"7","author":"Tameris","year":"2019","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.vaccine.2021.06.049_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30653-8","article-title":"BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial","author":"Prentice","year":"2021","journal-title":"Lancet Infectious Diseases"},{"key":"10.1016\/j.vaccine.2021.06.049_b0315","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.it.2013.04.004","article-title":"A small jab - a big effect: nonspecific immunomodulation by vaccines","volume":"34","author":"Benn","year":"2013","journal-title":"Trends in Immunology"},{"key":"10.1016\/j.vaccine.2021.06.049_b0320","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.celrep.2016.11.011","article-title":"Immunometabolic Pathways in BCG-Induced Trained Immunity","volume":"17","author":"Arts","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.vaccine.2021.06.049_b0325","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.trsl.2018.03.004","article-title":"Therapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer","volume":"197","author":"Alvarez-Arguedas","year":"2018","journal-title":"Transl Res."},{"key":"10.1016\/j.vaccine.2021.06.049_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103186","article-title":"Therapeutic efficacy of pulmonary live tuberculosis vaccines against established asthma by subverting local immune environment","volume":"64","author":"Tarancon","year":"2021","journal-title":"EBioMedicine."},{"key":"10.1016\/j.vaccine.2021.06.049_b0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008404","article-title":"New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia","volume":"16","author":"Tarancon","year":"2020","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.vaccine.2021.06.049_b0340","doi-asserted-by":"crossref","unstructured":"Esther Broset JP-S, Alex I. Kanno, Nacho Aguilo, Ana Isabel Dacosta, Irene Rivero-Calle, Jesus Gonzalo-Asensio, Camille Locht, Luciana C.C. Leite, Carlos Martin, Federico Martin\u00f3n-Torres. BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies. EBioMedicine 65 (2021) 103254 https:\/\/doiorg\/101016\/jebiom2021103254. 2021.","DOI":"10.1016\/j.ebiom.2021.103254"},{"key":"10.1016\/j.vaccine.2021.06.049_b0345","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"Journal of Urology"},{"key":"10.1016\/j.vaccine.2021.06.049_b0350","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.1202870109","article-title":"Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes","volume":"109","author":"Kleinnijenhuis","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2021.06.049_b0355","article-title":"Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection","volume":"2","author":"Dijkman","year":"2021","journal-title":"Cell Rep Med."},{"key":"10.1016\/j.vaccine.2021.06.049_b0360","article-title":"Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination","volume":"2","author":"Vierboom","year":"2021","journal-title":"Cell Rep Med."},{"key":"10.1016\/j.vaccine.2021.06.049_b0365","doi-asserted-by":"crossref","unstructured":"Lindestam Arlehamn CS, McKinney DM, Carpenter C, Paul S, Rozot V, Makgotlho E, et al. A Quantitative Analysis of Complexity of Human Pathogen-Specific CD4 T Cell Responses in Healthy M. tuberculosis Infected South Africans. PLoS Pathog. 2016;12:e1005760.","DOI":"10.1371\/journal.ppat.1005760"},{"key":"10.1016\/j.vaccine.2021.06.049_b0370","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.1073\/pnas.1015153108","article-title":"Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection","volume":"108","author":"Millington","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2021.06.049_b0375","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1016\/j.vaccine.2014.05.042","article-title":"Causes of variation in BCG vaccine efficacy: examining evidence from the BCG REVAC cluster randomized trial to explore the masking and the blocking hypotheses","volume":"32","author":"Barreto","year":"2014","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.06.049_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102761","article-title":"Live attenuated TB vaccines representing the three modern Mycobacterium tuberculosis lineages reveal that the Euro-American genetic background confers optimal vaccine potential","volume":"55","author":"Perez","year":"2020","journal-title":"EBioMedicine."},{"key":"10.1016\/j.vaccine.2021.06.049_b0385","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2020.02.024","article-title":"Renewing the Fight Against TB with an Old Vaccine","volume":"180","author":"Scriba","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2021.06.049_b0390","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/thx.38.11.806","article-title":"BCG: who were Calmette and Guerin?","volume":"38","author":"Sakula","year":"1983","journal-title":"Thorax"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21007994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21007994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:05:22Z","timestamp":1759403122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21007994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":78,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0264410X21007994"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.06.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MTBVAC, a live TB vaccine poised to initiate efficacy trials 100\u00a0years after BCG","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.06.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}